Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network : JNCCN Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D'Amico, A. V., Davis, B. J., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Horwitz, E. M., Ippolito, J. E., Kuettel, M. R., Lang, J. M., McKay, R., McKenney, J., Netto, G., Penson, D. F., Pow-Sang, J. M., Reiter, R., Richey, S., Roach Iii, M., Rosenfeld, S., Shabsigh, A., Spratt, D. E., Teply, B. A., Tward, J., Shead, D. A., Freedman-Cass, D. A. 2021; 19 (2): 134–43

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

View details for DOI 10.6004/jnccn.2021.0008

View details for PubMedID 33545689